Pharma
Strategies for combination therapy in oncology: Part two - Working with the “status quo”
This is the second article in a three-part series examining the commercial dynamics surrounding combination therapy in oncology across the US and Europe. In this article, we investigate strategies that manufacturers could consider to optimize pricing and access opportunities for their c...
Antimicrobial Resistance Policy Solutions
It is difficult to imagine someone who hasn’t called on antibiotics to help them through an infection or protect them during a surgery. Thanks to developments over the last 150 years, once life-threatening bacterial encounters have been relegated to minor inconveniences. Or have they? T...
Get to know the inflammatory bowel disease (IBD) team at the NIHR BioResource
Who are they, what a day looks like in the team and everything involved in making our Inflammatory Bowel Disease (IBD) team one of the core cogs in the workings of the NIHR BioResource! ...
Reflecting on our campaign to increase volunteer diversity
NIHR BioResource for Translational Research writes...As our 12-week campaign with Egality Health and eight community-based health advocacy organisations has come to a close, we’re reflecting on our successes and sharing some key learnings going forward. We also heard from some of our co...
Redundancy: A Golden-Ticket Opportunity (face to face or Virtual Event)
If you are in the Life Sciences, Pharma, Medical Devices or Health Tech industries, and whether you're currently facing potential redundancy, actively seeking a new opportunity, or have previously encountered redundancy and wish to share your experiences while extending a helping hand t...
Milner Therapeutics Institute to house world-class functional genomics laboratory, in new partnership with AstraZeneca and the Medical Research Council
The University of Cambridge announces a new partnership with AstraZeneca and the Medical Research Council (MRC) that will establish a new state-of-the-art functional genomics laboratory at the Milner Therapeutics Institute. ...
Are Free Energy Perturbation (FEP) methods suitable for your project?
Free Energy Perturbation (FEP) methods are a fast-evolving area of drug discovery, and Cresset Discovery’s dedicated team of expert modelers are establishing a rapidly growing portfolio of successfully completed FEP projects. There are a number of key data requirements that are necessar...
IPFL expands printing possibilities with new multi-material polyjet printer
Multi material production 3D Printing and prototyping IPFL, experts in plastic machining, fabrication and 3D printing, has begun running the latest J850 Polyjet 3D printer from Stratasys. The machine will support the company’s compilation of 3D printing technologies and expan...
Unleashing the potential of Micro 3D Printing with the BMF PµSL System
IPFL is at the forefront of micro 3D printing innovation with the BMF PµSL system, offering unparalleled precision in manufacturing microscale components. Ideal for aerospace, medical, and electronics industries, this advanced technology enables the creation of highly detailed parts pre...
Streamlining the design of PROTACs® and PROTAC linkers
Register here - Streamlining the design of PROTACs® and PROTAC linkers (cresset-group.com) ...